astria therapeutics glp-1 receptor agonist weight management diabetes treatments cardinal health GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon astria therapeutics glp-1 receptor agonist

[119] conducted a phase II clinical trial in patients with NASH, that is, a placebo-controlled trial of subcutaneous sommarutide in the treatment of NASH, and found that sommarutide treatment resulted in a significantly higher proportion of patients in remission of NASH compared with placebo

10.1016/j.pmn.2022.05.005 [DOI] [PubMed] [Google Scholar] 79.Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W (2023) Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling

Since then, research has continued, leading to newer, often more effective, and longer-acting versions

Type 1 diabetes is characterised by deficient insulin production by the pancreas

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 13 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)